Search Results
Your search for Staff matches 6666 pages
Showing 3201 - 3250
Joseph M. Unger, PhD, on the Impact of NCI-Sponsored Treatment Trials
Joseph M. Unger, PhD, of Fred Hutchinson Cancer Research Center, discusses findings from his study of the National Cancer Institute’s Clinical Trials Network, which has conducted publicly funded cancer research for more than 50 years. The substantial gains in life years for patients with cancer, he ...
Jonathan Lim, MBBS, MRCP: The Future of the Oncology Workforce Since the COVID-19 Pandemic
Jonathan Lim, MBBS, MRCP, of Christie NHS Foundation Trust and the Francis Crick Institute, discusses results of an ESMO survey, which showed that the risk of poor well-being, distress, and burnout has continued to rise since the onset of the COVID-19 pandemic, despite improved job performance and...
Recent FDA Approvals in Breast Cancer
In the past year, the U.S. Food and Drug Administration (FDA) approved five treatment options for patients with breast cancer, which are summarized herein. Abemaciclib Combination On October 12, 2021, the FDA approved abemaciclib (Verzenio) with endocrine therapy (tamoxifen or an aromatase...
Expert Point of View: Yuan Yuan, MD, PhD and Elizabeth Mittendorf, MD, PhD
Yuan Yuan, MD, PhD, a medical oncologist at City of Hope, Duarte, California, weighed in on the KEYNOTE-355 findings. “The study presented by Dr. Rugo on KEYNOTE-355 reconfirms the utility of adding immune checkpoint inhibitors to chemotherapy as front-line treatment for metastatic triple-negative ...
KEYNOTE-355: Pembrolizumab Plus Chemotherapy Improves Progression-Free Survival in PD-L1–Enriched Advanced Triple-Negative Breast Cancer
Pembrolizumab plus chemotherapy improved progression-free survival vs chemotherapy alone as first-line treatment of advanced or metastatic triple-negative breast cancer, according to the results of KEYNOTE-355.1 Progression-free survival was significantly improved with pembrolizumab plus...
Expert Point of View: Melinda L. Telli, MD
EA1131 study discussant, Melinda L. Telli, MD, Associate Professor of Medicine at Stanford University, Director of the Breast Cancer Program at the Stanford Cancer Institute, and Associate Director of the Stanford Women’s Cancer Center, commented: “At this point, capecitabine remains preferred as...
EA1131 Trial: Platinum Not Equal to Capecitabine for Residual Disease in Triple-Negative Breast Cancer
In patients with triple-negative breast cancer who have residual disease after neoadjuvant chemotherapy, adjuvant capecitabine remains the standard of care. In the multicenter randomized noninferiority EA1131 trial, which included primarily basal tumors, noninferiority of adjuvant platinum over...
Sacituzumab Govitecan-hziy Improves Survival vs Single-Agent Chemotherapy in Metastatic Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Aditya Bardia, MD, of the Division of Medical Oncology, Massachusetts General Hospital Cancer Center, and colleagues, the phase III ASCENT trial has shown prolonged progression-free and overall survival with the Trop-2–directed antibody-drug...
Expert Point of View: Melinda L. Telli, MD
The invited discussant of GeparNuevo,1 Melinda L. Telli, MD, Associate Professor of Medicine at Stanford University School of Medicine, Director of the Breast Cancer Program at the Stanford Cancer Institute, and Associate Director of the Stanford Women’s Cancer Center, welcomed the additional data...
Neoadjuvant Durvalumab Improves Long-Term Outcomes in the GeparNuevo Trial
In the phase II GeparNuevo trial, patients with early triple-negative breast cancer receiving the PD-L1 inhibitor durvalumab in addition to chemotherapy as neoadjuvant therapy saw improvements in long-term outcomes. The results were presented at the 2021 ASCO Annual Meeting by Sibylle Loibl, MD,...
Expert Point of View: Giuseppe Curigliano, MD, PhD
Invited discussant Giuseppe Curigliano, MD, PhD, Associate Professor of Medical Oncology at the University of Milan, Italy, and Head of the Division of Early Drug Development at the European Institute of Oncology, said the “clear” findings of KEYNOTE-5221 are “practice-changing.” However, the ideal ...
KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer
The latest analysis of the phase III KEYNOTE-522 trial demonstrated significant improvements in clinical outcomes with pembrolizumab plus chemotherapy vs chemotherapy alone as a neoadjuvant/adjuvant treatment of triple-negative breast cancer.1 This is the first large, randomized, phase III trial to ...
Early Triple-Negative Breast Cancer: Are Checkpoint Inhibitors Ready for Neoadjuvant or Adjuvant Use?
Recent clinical trials have been encouraging for the neoadjuvant or adjuvant use of immune checkpoint inhibitors in triple-negative breast cancer, but is this approach ready for the clinic? This question was addressed at the 38th Miami Breast Cancer Conference, held virtually this year, by Adam M....
Margetuximab-cmkb Plus Chemotherapy Prolongs Progression-Free Survival in Heavily Pretreated HER2 Positive Breast Cancer
As reported in JAMA Oncology by Hope S. Rugo, MD, of the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, and colleagues, the phase III SOPHIA trial has shown significantly prolonged progression-free survival with margetuximab-cmkb plus chemotherapy vs...
ADAPT Trial: ‘Excellent’ Outcomes Reported With Neoadjuvant Dual HER2 Therapy in Breast Cancer
The first overall survival analysis of the WGS-ADAPT HER2+/HR– study, which evaluated neoadjuvant therapy in patients with hormone receptor–negative, HER2-positive disease, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or with the chemotherapy-free regimen of...
Expert Point of View: Evandro de Azambuja, MD, PhD
Invited discussant of the Short-HER trial, Evandro de Azambuja, MD, PhD, Head of the Medical Support Team at the Institut Jules Bordet, Brussels, acknowledged the good outcomes in low- and intermediate-risk patients treated with either a short or long duration of trastuzumab but said 1 year of the...
Long-Term Analysis of Short-HER Trial of Adjuvant Trastuzumab
Long-term analysis of the Short-HER trial showed that 9 weeks of adjuvant trastuzumab conveyed benefits comparable to a 1-year course in patients with early HER2-positive breast cancer deemed to be at low or intermediate risk for recurrence. High-risk patients, however, derived considerably more...
Novel HER2-Targeted Therapies Pose Sequencing Challenges
With three new HER2-targeted therapies approved over the past year or two alone, the treatment landscape for patients with metastatic breast cancer has become increasingly crowded. In the third-line setting and beyond, there are now at least eight HER2-targeted agents approved by the U.S. Food and...
Expert Point of View: C. Kent Osborne, MD
C. Kent Osborne, MD, Founding Director of the Dan L. Duncan Comprehensive Cancer Center and the Dudley and Tina Sharp Chair for Cancer Research, Baylor College of Medicine, Houston, said in a press briefing that the results of the study were clear, but the explanation for the findings is less so....
RxPONDER: Many Postmenopausal Patients With Node-Positive Breast Cancer Can Avoid Chemotherapy
The SWOG S1007 RxPONDER trial evaluated the benefit of chemotherapy in women with early-stage hormone receptor–positive, HER2-negative breast cancer and node-positive disease.1 The data showed that many postmenopausal women can skip adjuvant chemotherapy, based on a 46% reduction in the risk of...
Expert Point of View: C. Kent Osborne, MD, and Ruth M. O’Regan, MD
Commentary for monarchE and PENELOPE-B was provided by C. Kent Osborne, MD, and Ruth M. O’Regan, MD, respectively. Dr. Osborne is Professor of Medicine, Hematology, and Oncology and the Dudley and Tina Sharp Chair for Cancer Research at Baylor College of Medicine, as well as Founding Director of...
A Tale of Two CDK4/6 Inhibitors in Early Breast Cancer
The primary outcome analysis of the phase III monarchE trial, an update of previous data, continued to show significant benefit for abemaciclib in the adjuvant setting, reducing the risk for invasive disease recurrence by 28.7%. Meanwhile, the first results of the phase III PENELOPE-B trial of...
Addition of Adjuvant Palbociclib to Ongoing Endocrine Therapy in HR-Positive, HER2-Negative Early Breast Cancer: PALLAS Trial
As reported in The Lancet Oncology by Erica L. Mayer, MD, and colleagues, the second interim analysis of the phase III PALLAS trial showed no improvement in invasive disease–free survival with the addition of adjuvant palbociclib to ongoing endocrine therapy in patients with hormone receptor...
Expert Point of View: Nadine M. Tung, MD
Formal discussant of the OlympiA trial, Nadine M. Tung, MD, Director of Breast Medical Oncology and the Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center and Harvard Medical School, was enthusiastic about the ability of olaparib to improve invasive disease–free survival ...
OlympiA Trial: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early Breast Cancer
Adjuvant therapy with the PARP inhibitor olaparib for 1 year extended disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA1/2 germline (inherited) mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented at the...
Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer: What’s Next?
Because of their well-established efficacy, inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are the standard of care in the treatment of hormone receptor–positive, HER2-negative metastatic breast cancer. The question now is this: After disease progresses on a CDK4/6 inhibitor and endocrine...
John V. Cox, DO, MBA, on Reshaping Practice Models to Better Care for Patients With Cancer
John V. Cox, DO, MBA, of The University of Texas Southwestern Medical Center, summarizes his Joseph V. Simone Lecture, in which he stressed the need for coordinated care among practices. The concept of oncology medical homes, he says, has evolved to a broader-based model in which oncologists...
Study Examines Cost of Cancer Care in the United States in 2018
Care for the 15 most prevalent types of cancer in the United States cost approximately $156.2 billion for about 402,000 privately insured adult patients in 2018, according to a report published by Nicholas G. Zaorsky, MD, and colleagues in JAMA Network Open. The research team also found that...
Goal-Focused Emotion-Regulation Therapy for Young Adult Testicular Cancer Survivors
Psychological therapy may reduce adverse biobehavioral effects of testicular cancer in young adult survivors, according to a pilot study published by Hoyt et al in the American Journal of Men’s Health. Biobehavior is the interaction of biologic processes and behavior. The recently published...
Study Tracks Parental Hesitancy Trends Over the HPV Vaccine From 2010 to 2019
A study that tracked parental opinion about the human papillomavirus (HPV) vaccine showed that after hesitancy decreased for several years, hesitancy has now either stabilized or increased in some ethnic and age groups, according to results presented by Adjei Boakye et al at the 14th AACR...
The Wistar Institute Appoints Italo Tempera, PhD, as Associate Director for Cancer Research Career Enhancement
The Wistar Institute has announced the appointment of Italo Tempera, PhD, as Associate Director for Cancer Research Career Enhancement at the Institute’s Cancer Center. Dr. Tempera, who is also Associate Professor in the Gene Expression & Regulation Program, will lead the educational mission of ...
Michael Boyer, MBBS, FRACP, PhD, Honored With Adi F. Gazdar IASLC Merit Award
The International Association for the Study of Lung Cancer (IASLC) has named Michael Boyer, MBBS, FRACP, PhD, as the 2021 recipient of the Adi F. Gazdar IASLC Merit Award. The announcement was made during the IASLC 2021 World Conference on Lung Cancer. In 2019, the IASLC Board of Directors...
MSK Announces New Senior Vice President, Chief Nurse Executive, and Chair of Nursing
Memorial Sloan Kettering Cancer Center (MSK) has appointed Tracy Gosselin, PhD, RN, AOCN, NEA-BC, FAAN, as Senior Vice President, Chief Nurse Executive, and Chair of Nursing, effective November 2021. Dr. Gosselin currently serves as Chief Nursing & Patient Care Services Officer at Duke...
Roswell Park and University of Chicago Medicine Comprehensive Cancer Centers Awarded Nearly $9M for Ovarian Cancer Research
For years, scientists at Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center have devoted themselves to research to better understand ovarian cancer. Now, teams of researchers from these two leading centers are combining efforts after together ...
AACR Announces 2021 Distinguished Lectureship on the Science of Cancer Health Disparities
The American Association for Cancer Research (AACR) has announced Graham A. Colditz, MD, DrPH, MPH, as the recipient of the 2021 AACR Distinguished Lectureship on the Science of Cancer Health Disparities. Dr. Colditz presented his award lecture, “Making Progress, Together: An Inclusive, Broad-Based ...
Oncology Care Remains Under Strain in the Ongoing COVID-19 Pandemic
The resurging COVID-19 pandemic has reawakened challenges for patients and physicians—ones we all hoped were over—and presented stressful situations for patients and providers. Hospitals in some states, particularly those with lower vaccination rates, have faced levels of urgent illness that have...
Divya Gupta, MD, on Improving Advance Care Planning Conversations With Patients
Divya Gupta, MD, of the Stanford Cancer Center, discusses an intervention utilizing a computer model and lay care coaches to improve advance care planning conversations with patients who have metastatic cancer. The study, Dr. Gupta reports, showed a trend toward less intensive care for patients at...
FDA Pipeline: Recent Reviews, Designations, Applications, and Authorizations in the Oncology Space
Over the past month, the U.S. Food and Drug Administration (FDA) issued several regulatory decisions for novel treatments for patients with cancer. Priority Review for Relatlimab and Nivolumab Fixed-Dose Combination in Unresectable or Metastatic Melanoma The FDA accepted for Priority Review the...
Effect of Chronic Stress on Treatment Completion and Survival Outcomes in Patients With Breast Cancer
Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node–positive or high-risk lymph node–negative HER2-negative breast cancer, according to results presented by Samilia Obeng-Gyasi, MD, MPH, at the 14th ...
ARAMIS Analysis: Darolutamide Shows Similar Benefits for Black Patients as Observed in the Overall Population
Black patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide had clinical outcomes similar to those observed in the overall clinical trial population, according to results from the phase III ARAMIS trial presented by Neal Shore, MD, at the 14th AACR...
Francis S. Collins, MD, PhD, to Step Down as Director of the National Institutes of Health
On October 5, Francis S. Collins, MD, PhD, announced his decision to end his tenure as Director of the National Institutes of Health (NIH) by the end of the year. Dr. Collins is the longest-serving presidentially appointed NIH Director, having served three U.S. presidents over more than 12 years....
Divya A. Parikh, MD, on Improving Care Documentation With a Patient Conversation Guide
Divya A. Parikh, MD, of Stanford University School of Medicine, discusses findings that suggest an evidence-based tool, the Serious Illness Conversation Guide, may engage patients with metastatic or recurrent urologic cancer in goals-of-care conversations, potentially resulting in an increase of...
How ASCO Is Expanding Its Commitment to Diversity and Equity in Cancer Care
Ensuring equitable cancer care for every patient, everywhere has been embedded into ASCO’s mission statement since the Society’s inception nearly 60 years ago. Nevertheless, events of the past year, including the ongoing COVID-19 pandemic, which has disproportionally impacted minority communities, ...
Donations to St. Jude Children’s Research Center Soar; Inspiration4 SpaceX Journey Exceeds $200 Million Goal
On September 15, 2021, SpaceX launched the Inspiration4 mission, sending four civilians on a 3-day trip orbiting the earth. The passengers were the first to travel on an all-civilian space journey in an effort to further scientific and aerospace research while at the same time raise funds for...
FDA Recognizes Memorial Sloan Kettering Database of Molecular Tumor Marker Information
On October 7, the U.S. Food and Drug Administration (FDA) granted recognition to a partial listing of the Memorial Sloan Kettering Cancer Center Oncology Knowledge Base (OncoKB) as the first tumor mutation database to be included in the Public Human Genetic Variant Databases. The FDA recognized a...
President Biden Appoints Members to National Cancer Advisory Board
President Biden announced the appointment of seven distinguished clinicians and researchers to the National Cancer Advisory Board, which plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. President Biden...
Courtney Williams, DrPH, on Cancer Survivors: Working Together to Improve Patient Adherence
Courtney Williams, DrPH, of the National Cancer Institute, discusses the costs associated with cancer survivors who don’t take their medications and cites the need for research to better understand whether residing in an urban or rural area may affect prescription adherence, and what interventions...
Benjamin W. Corn, MD, on Integrating Hope Into Clinical Oncology
Benjamin W. Corn, MD, of Shaare Zedek Medical Center in Jerusalem, discusses hope: what it takes for hope to thrive; how he and his colleagues are helping patients and providers become more hopeful through workshops; and his collaboration with the Southwest Oncology Group to aid patients, through...
Jenny F. Seligmann, MBChB, PhD, on Colorectal Cancer: Adavosertib Compared With Active Monitoring
Jenny F. Seligmann, MBChB, PhD, of the University of Leeds, discusses phase II findings that suggest adavosertib improved progression-free survival, compared with active monitoring, by inhibiting the WEE1 kinase in patients with RAS- and TP53-mutant metastatic colorectal cancer. In the trial,...
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor ALL
On October 1, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (Tecartus), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ZUMA-3 Efficacy was evaluated ...
